BIRC5 and cancer: As shown in Fig. 12, compound 6 and 37a, which showed comparatively potent cytotoxicity in tested cancer cell lines, indeed displayed selective and dose-dependent survivin inhibition effects on human melanoma A375 and M14 cells after 24 hours treatment at concentrations from 2 to 20 μmol/L.